SEOM clinical guideline in ovarian cancer (2020)
A Redondo 1 , E Guerra 2 , L Manso 3 , C Martin-Lorente 4 , J Martinez-Garcia 5 , J A Perez-Fidalgo 6 , M Q Varela 7 , M J Rubio 8 , M P Barretina-Ginesta 9 , A Gonzalez-Martin 10
Despite remarkable advances in the knowledge of molecular biology and treatment, ovarian cancer remains the leading cause of death from gynecologic cancer.
In the last decade, there have been important advances both in systemic and surgical treatment. However, there is no doubt that the incorporation of PARP inhibitors as maintenance after the response to platinum-based chemotherapy, first in recurrent disease and recently also in first line, will change the natural history of the disease.
The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of ovarian cancer, and to provide evidence-based recommendations for clinical practice.
CITA DEL ARTÍCULO Clin Transl Oncol. 2021 Jan 30. doi: 10.1007/s12094-020-02545-x